Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies

Human epithelial ovarian carcinoma is well-known as a sex steroid-dependent neoplasm, but the possible biological significance of progesterone receptor (PR) in this cancer remains controversial. Recently, two isoforms of human PR, PRA and PRB, have been characterized and different functional characteristics have been reported for these two isoforms. We therefore examined immunohistochemistry (107 cases) and reverse transcription-polymerase chain reaction (RT-PCR) (16 cases) for PRA, PRB, and oestrogen receptor-a (ER-a). Labeling indices (LI) for PRA and PRB were 2.4 and 43.6, respectively, and the difference was statistically significant. PRB LI, but not PRA LI, as well as performance status, stage, and residual tumour turned out to be independent prognostic factors following multivariate analysis. There was also a significant correlation between ER-a LI and PRB LI (r = 0.595, P < 0.0001), suggestive of a possible interaction between these two receptors. RT-PCR also detected the expression of PR isoform transcripts in the same pattern as was observed with immunohistochemistry. Results of these studies indicate that PRA and PRB both mediate distinct pathways of progesterone action in ovarian carcinoma. Moreover, it is important to examine PRB LI as a prognostic factor in the cases of human epithelial ovarian carcinoma. © 2000 Cancer Research Campaign http://www.bjcancer.com

[1]  C. Clarke,et al.  Colocalization of progesterone receptors A and B by dual immunofluorescent histochemistry in human endometrium during the menstrual cycle. , 1999, The Journal of clinical endocrinology and metabolism.

[2]  M. Piver,et al.  Progesterone receptor status is a significant prognostic variable of progression-free survival in advanced epithelial ovarian cancer. , 1998, American journal of clinical oncology.

[3]  H. Gabra,et al.  Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogen. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  H. Critchley,et al.  Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system. , 1998, Human reproduction.

[5]  K. Horwitz,et al.  Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action. , 1998, Cancer research.

[6]  D. Baird,et al.  Progesterone receptor subtype B is differentially regulated in human endometrial stroma. , 1998, Molecular human reproduction.

[7]  T. Tamaya,et al.  Expression of Progesterone Receptor Form A and B mRNAs in Uterine Leiomyoma , 1998, Tumor Biology.

[8]  S. Langdon,et al.  Estrogen regulation of transforming growth factor-α in ovarian cancer , 1998, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  P. Giangrande,et al.  Mapping and Characterization of the Functional Domains Responsible for the Differential Activity of the A and B Isoforms of the Human Progesterone Receptor* , 1997, The Journal of Biological Chemistry.

[10]  H. Sasano,et al.  Colocalization of 11 beta-hydroxysteroid dehydrogenase type II and mineralocorticoid receptor in human epithelia. , 1997, The Journal of clinical endocrinology and metabolism.

[11]  N. Weigel,et al.  Differential expression of uterine progesterone receptor forms A and B during the menstrual cycle , 1997, The Journal of Steroid Biochemistry and Molecular Biology.

[12]  D. Charnock-Jones,et al.  Distribution of the A and B forms of the progesterone receptor messenger ribonucleic acid and protein in uterine leiomyomata and adjacent myometrium. , 1997, Human reproduction.

[13]  P. Tuohimaa,et al.  Expression of the chicken progesterone receptor forms A and B is differentially regulated by estrogen in vivo. , 1997, Biochemical and biophysical research communications.

[14]  N. Harada,et al.  Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma. , 1996, The Journal of clinical endocrinology and metabolism.

[15]  J. P. Geisler,et al.  Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary. , 1996, Gynecologic oncology.

[16]  J. Graham,et al.  Progesterone receptor A and B protein expression in human breast cancer , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[17]  J. Graham,et al.  Preferential Stimulation of Human Progesterone Receptor B Expression by Estrogen in T-47D Human Breast Cancer Cells (*) , 1995, The Journal of Biological Chemistry.

[18]  T. Tamaya,et al.  Expression of progesterone receptor form A and B mRNAs in gynecologic malignant tumors. , 1995, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[19]  B. Katzenellenbogen,et al.  Inhibitory cross-talk between steroid hormone receptors: differential targeting of estrogen receptor in the repression of its transcriptional activity by agonist- and antagonist-occupied progestin receptors , 1995, Molecular and cellular biology.

[20]  D. McDonnell,et al.  The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells , 1994, Molecular and cellular biology.

[21]  E. Felip,et al.  Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. , 1994, Gynecologic oncology.

[22]  B. O’Malley,et al.  Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. , 1993, Molecular endocrinology.

[23]  G. Wampler,et al.  Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  W. Sauerbrei,et al.  Steroid receptors in ovarian carcinoma: immunohistochemical determination may lead to new aspects. , 1992, Gynecologic oncology.

[25]  E. Yordan,et al.  Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  B. Slotman,et al.  Endocrine factors in common epithelial ovarian cancer. , 1991, Endocrine reviews.

[27]  M. Schemper,et al.  Oestrogen and progesterone receptor content as a prognostic factor in advanced epithelial ovarian carcinoma , 1990, British journal of obstetrics and gynaecology.

[28]  C. Clarke,et al.  Progestin regulation of cellular proliferation. , 1990, Endocrine reviews.

[29]  P Chambon,et al.  Two distinct estrogen‐regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. , 1990, The EMBO journal.

[30]  T. Nagasaka,et al.  Study of ovarian tumors treated at Nagoya University Hospital, 1965-1988. , 1990, Gynecologic oncology.

[31]  B. Katzenellenbogen,et al.  Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: interrelationships among insulin/insulin-like growth factor-I, serum, and estrogen. , 1990, Endocrinology.

[32]  S. Masood,et al.  Clinical correlation of hormone receptor status in epithelial ovarian cancer. , 1989, Gynecologic oncology.

[33]  J. Stolk,et al.  Importance of steroid receptors and aromatase activity in the prognosis of ovarian cancer: high tumor progesterone receptor levels correlate with longer survival. , 1989, Gynecologic oncology.

[34]  M. Friedlander,et al.  The relationship of steroid receptor expression to nuclear DNA distribution and clinicopathological characteristics in epithelial ovarian tumors. , 1989, Gynecologic oncology.

[35]  F. Landoni,et al.  Steroid receptors in epithelial ovarian carcinoma: relation to clinical parameters and survival. , 1988, Cancer research.

[36]  M. Piver,et al.  The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  R. Evans,et al.  The steroid and thyroid hormone receptor superfamily. , 1988, Science.

[38]  J. V. Miller,et al.  Monoclonal antibodies to human progesterone receptor: characterization by biochemical and immunohistochemical techniques. , 1987, Endocrinology.

[39]  P. Chambon,et al.  Cloning of the chicken progesterone receptor. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[40]  A. Heintz,et al.  Cytoreductive surgery in ovarian carcinoma: Feasibility and morbidity , 1986 .

[41]  N. Geller,et al.  Prognostic factors in advanced ovarian carcinoma. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  M. Volm,et al.  Prognostic relevance of ploidy, proliferation, and resistance-predictive tests in ovarian carcinoma. , 1985, Cancer research.

[43]  A. Zetterberg,et al.  Prognostic significance of nuclear DNA content in serous ovarian tumors. , 1984, Cancer research.

[44]  A. Kauppila.  Progestin Therapy of Endometrial, Breast and Ovarian Carcinoma , 1984, Acta obstetricia et gynecologica Scandinavica.

[45]  K. Horwitz,et al.  In situ photolinked nuclear progesterone receptors of human breast cancer cells: subunit molecular weights after transformation and translocation. , 1983, Endocrinology.

[46]  K. Horwitz.  Is a functional estrogen receptor always required for progesterone receptor induction in breast cancer? , 1981, Journal of Steroid Biochemistry.

[47]  W. McGuire,et al.  The value of estrogen and progesterone receptors in the treatment of breast cancer , 1980, Cancer.

[48]  N. Bloom,et al.  The role of progesterone receptors in the management of advanced breast cancer , 1980, Cancer.

[49]  T. Benraad,et al.  Do Estrogen and Progesterone Receptors (E2R and PR) in Metastasizing Endometrial Cancers Predict the Response to Gestagen Therapy? , 1980, Acta obstetricia et gynecologica Scandinavica.

[50]  R. Fisher,et al.  Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. , 1978, The New England journal of medicine.

[51]  W. McGuire.  Steroid receptors in human breast cancer. , 1978, Cancer research.

[52]  J.,et al.  Responses in the brain of estrogen receptor a-disrupted mice , 1997 .

[53]  E. Milgrom,et al.  Molecular action of progesterone. , 1990, The International journal of biochemistry.

[54]  O. Iversen,et al.  Steroid receptor content in human ovarian tumors: survival of patients with ovarian carcinoma related to steroid receptor content. , 1986, Gynecologic oncology.

[55]  R. Cleary,et al.  Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: therapeutic implications. , 1981, American journal of obstetrics and gynecology.